Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure

Nephrology Dialysis Transplantation

Volumn 12, Issue 11, 1997, Pages 2349-2354

  Boccardo, P ^a,c   Melacini, D ^a   Rota, S ^a   Mecca, G ^a   Boletta, A ^a   Casiraghi, F ^a   Gianese, F ^b  

^a OSPEDALI RIUNITI   (Italy)

^b Medical Department   (Italy)

^c MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Anticoagulation; Clinical trial; Dermatan sulphate; Haemodialysis; Heparin

Indexed keywords

CREATININE; DERMATAN SULFATE; HEPARIN; THROMBOPLASTIN; UREA;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBUS; TREATMENT PLANNING; UREA BLOOD LEVEL;

AGED; ANTICOAGULANTS; CROSS-OVER STUDIES; DERMATAN SULFATE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RENAL DIALYSIS; THROMBOSIS;

EID: 0030706195     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.11.2349     Document Type: Article

References (23)

1. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 1994; 89: 1449-1468
2. Viganò G, Schieppati A, Remuzzi G. Thrombogenesis and anticoagulation in patients undergoing chronic hemodialysis. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF. eds. Replacement of Renal Function by Dialysis. Kluwer Academic Publishers, Dordrecht, 1996; 323-332
3. Kandrotas RJ, Gal P, Douglas JB, Deterding J. Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability. Pharmacotherapy 1990; 10: 349-356
4. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-1214
5. Bendayan P, Boccalon H, Dupouy D, Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994; 71: 576-580
6. Agnelli G, Gianese F. Dermatan sulfate: biological and pharmacological properties; clinical applications. In: Goldhaber SZ, ed. Prevention of Venous Thromboembolism. Marcel Dekker. New York, 1993; 287-313
7. Dawes J. Smith P. The interaction of dermatan sulphate MF701 and heparin with platelets and plasma: implications for platelet-related side-effects of therapy. Thromb Haemost 1993; 69: 700 (abstract 574)
8. Agnelli G, Iorio A, De Angelis V, Nenci GG. Dermatan sulphate in heparin-induced thrombocytopenia. Lancet 1994; 344: 1295-1296
9. Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 1990; 63: 505-509
10. Parrish RF, Fair WR. Selective binding of zinc ions to heparin rather than to other glycosaminoglycans. Biochem J 1981; 193: 407-410
11. Agnelli G, Cosmi B, Di Filippo P et al. A randomized, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 67: 203-208
12. Prandoni P, Meduri F, Cuppini S et al. Dermatan sulfate: a safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 1992; 79: 505-509
13. Cohen AT, Phillips MJ, Edmonson RA et al. A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty. Thromb Haemost 1994; 72: 793-798
14. Lane DA, Ryan K, Ireland H et al. Dermatan sulphate in haemodialysis. Lancet 1992; 339: 334-335
15. Ryan KE, Lane DA, Flynn A et al. Antithrombotic properties of dermatan sulphate (MF701) in haemodialysis for chronic renal failure. Thromb Haemost 1992; 68: 563-569
16. Nurmohamed MT, Knipscheer HC, Stevens P et al. Clinical experience with a new anticoagulant (dermatan sulfate) in chronic hemodialysis patients. Clin Nephrol 1993; 39: 166-171
17. Gianese F, Nurmohamed MT, Imbimbo BP, Büller HR, Berckmans RJ, ten Gate JW. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure. Br J Clin Pharmacol 1993; 35: 335-339
18. Nurmohamed MT, Knipscheer HC, Gianese F et al. No clinically relevant accumulation of dermatan sulfate (DS) during chronic use in hemodialysis, Thromb Haemost 1993; 69: 1118 (abstract 2055)
19. Mingardi G, Perico N, Pusineri F et al. Heparin for hemodialysis: practical guidelines for administration and monitoring. Int J Artif Organs 1984; 7: 269-274
20. Daugirdas JT. The post:pre dialysis plasma urea nitrogen ratio to estimate Kt/V and NPCR: mathematical modeling. Int J Artif Organs 1989; 12: 411-419
21. Aleviadrou BJ, Moake JL, Turner NA et al. Real-time analysis of shear dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81: 1263-1276
22. Dupouy D, Sié P, Dol F, Boneu B. A simple method to measure dermatan sulfate at submicrogram concentrations in plasma. Thromb Haemost 1988; 60; 236-239
23. Turner NA, Moake JL, Kamat SG et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 1995; 91: 1354-1362